Case Comprehensive Cancer Center: Esophageal Neoplasms trials

The registry lists 12 Esophageal Neoplasms studies with Case Comprehensive Cancer Center as lead sponsor. 2 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 2Phase 2 7No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal AdenocarcinomaRecruitingNCT07222657Phase 2
• EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.RecruitingNCT06263088Not applicable
• Endoesophageal Brachytherapy for Patients With Esophageal CancerCompletedNCT03335813Not applicableResults posted
• Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination ChemotherapyTerminatedNCT02392377Phase 2Results posted
• Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)TerminatedNCT01395537Phase 1/2Results posted
• Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or StomachCompletedNCT00601705Phase 2Results posted
• Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction CancerCompletedNCT00268346Phase 2Results posted
• DRIHNC - Dehydration Reduction in Head & Neck CancerCompletedNCT03799380Not applicable
• FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal AdenocarcinomaActive, not recruitingNCT02037048Phase 2
• Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal JunctionTerminatedNCT00732745Phase 1
• Cryotherapy for Barrett's Esophagus and Early Esophageal CancersCompletedNCT00650988Early Phase 1
• Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction CancerCompletedNCT00258323Phase 2